Menu Search
Equities

Novo Nordisk A/S

NOVO B:CPH

Novo Nordisk A/S

Actions
Health CarePharmaceuticals & Biotechnology
  • Price (DKK)321.40
  • Today's Change2.35 / 0.74%
  • Shares traded1.84m
  • 1 Year change0.83%
  • Beta1.3689
Data delayed at least 15 minutes, as of Jul 17 2019 15:59 BST.
More ▼

Financials data is unavailable for this security.

Inc stmt in DKKIncome statement in DKKView more

Year on year Novo Nordisk A/S had little change in net income (from 38.13bn to 38.63bn). Revenues were also little changed (from 111.70bn to 111.83bn.)
Gross margin84.10%
Net profit margin33.56%
Operating margin42.94%
Return on assets37.63%
Return on equity83.71%
Return on investment73.16%
More ▼

Cash flow in DKKView more

In 2018, cash reserves at Novo Nordisk A/S fell by 1.53bn. However, the company earned 45.03bn from its operations for a Cash Flow Margin of 40.26%. In addition the company used 12.08bn on investing activities and also paid 34.52bn in financing cash flows.
Cash flow per share17.64
Price/Cash flow per share13.96
Book value per share20.19
Tangible book value per share17.93
More ▼

Balance sheet in DKKView more

Novo Nordisk A/S has a Debt to Total Capital ratio of 8.36%.
Current ratio0.963
Quick ratio0.6555
Total debt/total equity0.0913
Total debt/total capital0.0836
More ▼

Growth rates in DKK

Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 3.82% and 3.55%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Biotechnology & Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
Div yield(5 year avg)2.32%
Div growth rate (5 year)12.61%
Payout ratio (TTM)39.49%
EPS growth(5 years)11.25
EPS (TTM) vs
TTM 1 year ago		1.04
More ▼
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.